SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only ...
“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results